Racializing drug design: implications of pharmacogenomics for health disparities.
Current practices of using "race" in pharmacogenomics research demands consideration of the ethical and social implications for understandings of group difference and for efforts to eliminate health disparities. This discussion focuses on an "infrastructure of racialization" created by current trajectories of research on genetic differences among racially identified groups, the use of race as a proxy for risk in clinical practice, and increasing interest in new market niches by the pharmaceutical industry. The confluence of these factors has resulted in the conflation of genes, disease, and race. I argue that public investment in pharmacogenomics requires careful consideration of current inequities in health status and social and ethical concerns over reifying race and issues of distributive justice.
Lee
Sandra Soo-Jin
SS
Stanford Center for Biomedical Ethics, Stanford University, Palo Alto, CA 94304, USA. sandra.lee@stanford.edu
D015195:Drug Design; D006291:Health Policy; D006297:Health Services Accessibility; D006801:Humans; D010597:Pharmacogenetics / Q000941:ethics*; D044469:Racial Groups; D014481:United States